NeurologyLive Friday 5 — February 7, 2020


Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 7, 2020.

Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Risdiplam Effective in Spinal Muscular Atrophy Type 2 and 3

The study is the first placebo-controlled trial to include non-ambulant adults with spinal muscular atrophy type 2 or 3.


2: Fenfluramine Shows Success in Lennox-Gastaut Phase 3 Topline Data

The investigational therapy met its primary end point, showing superiority to placebo in reducing the frequency of drop seizures in patients with Lennox-Gastaut syndrome.


3: Sanofi's Investigational Multiple Sclerosis Drug Reduces Disease Activity

Sanofi observed a dose-response relationship based on reduction of new active gadolinium-enhancing T1-hyperintense lesions after 12 weeks of treatment with SAR442168.


4: Ultrasound-Guided vs Anatomical-Localization of Injectables

Comparing accuracy of ultrasound-guided vs anatomical localization of botulinum toxic injections into cadaver salivary glands.


5: Smartphone Videos May Be Reliable Resource to Aid Seizure Diagnosis

Recently published data showed that one-quarter of the smartphone videos were correctly diagnosed by 100% of the reviewing physicians.


Related Videos
Renã A. S. Robinson, PhD
Kevin Church, PhD
Merit Cudkowicz, MD, MSc
Jessica Ailani, MD
Frederic Schaper, MD, PhD
Jaime Imitol, MD
Jason M. Davies, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.